Clinical Trial Update: Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pixantrone + rituximab versus gemcitabine + rituximab in aggressive B-cell non-Hodgkin lymphoma and follicular grade 3 lymphoma after re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• gemcitabine + rituximab
• pixantrone + rituximab

Snippet

Sponsor: CTI BioPharma | Conditions: Diffuse Large B-cell Lymphoma, de Novo DLBCL | Phase 3 | Status: COMPLETED | Results posted: 2021-11-19